This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) (NCT05494736), a non-randomized phase 1 study. The primary outcome is Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT05494736 |
| Phase | Phase 1 |
| Condition | Human Immunodeficiency Virus |
| Allocation | Non-Randomized |
| Design model | Sequential |
| Masking | None (open label) |
| Enrollment | 20 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Merck Sharp & Dohme LLC |
| Results posted | Yes |
2. Clinical Question
Population
ART-naïve participants living with HIV-1 infection. The registry reports an enrollment of 20.
Intervention
A single oral dose of MK-8527, studied at 1.0 mg, 0.5 mg, or 0.25 mg.
Comparator
The study was nonrandomized and does not describe a like-for-like control group. The dose groups should not be interpreted as randomized comparisons.
Primary question
What mean change from baseline in plasma HIV-1 RNA was observed 168 hours after a single dose of MK-8527?
The registry describes a phase 1 study assessing safety, tolerability, pharmacokinetics, and antiviral activity after one dose. Its stated primary hypothesis was that, at a dose considered safe and generally well tolerated, MK-8527 would show antiviral activity measured by a reduction from baseline in plasma HIV-1 RNA of ≥1.0 log10 copies/mL.
The primary endpoint is the change in plasma HIV-1 RNA from baseline to 168 hours after dosing. However, the numerical estimate and its confidence interval are not reported in the registry record. Therefore, the record does not establish whether the observed change met the stated threshold, or how precisely any change was estimated. The study also assessed MK-8527 exposure and its active triphosphate form in blood cells, along with safety outcomes. These objectives provide context for the study but do not substitute for a reported primary endpoint result.
3. Trial Design
This was a phase 1, completed, single-dose clinical trial of MK-8527 in ART-naïve participants with HIV-1 infection. The registry lists an enrollment of 20, a start date of 2022-11-17, and a primary completion date of 2024-01-31. It describes the study as nonrandomized, unmasked, and sequential. These features mean that the registry does not describe a blinded, randomized allocation of participants to dose groups.
The three dose descriptions are a single oral dose of MK-8527 at 1.0 mg, 0.5 mg, or 0.25 mg. The brief summary says that four arms were initially planned but Arm D was never initiated because the primary objectives were achieved after completion of Arms A to C. The adverse-event listing labels the 0.25 mg group “Panel D,” while the arm descriptions call that dose Panel C. The registry record does not explain this difference in labels.
The primary endpoint concerns mean change in plasma HIV-1 RNA at 168 hours after dosing. Secondary outcomes include measures of MK-8527 triphosphate exposure in peripheral blood mononuclear cells and MK-8527 exposure in plasma, as well as concentration and timing measures. These are pharmacokinetic outcomes, distinct from the primary RNA endpoint.
Because dose allocation was not randomized, observed differences between dose groups cannot be read as controlled causal contrasts. Details of the sequence used to assign doses, the dose-escalation rules, and any protocol stopping criteria are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Participants were recruited at study sites in Romania and South Africa. A total of 4 arms was initially planned, but Arm D was never initiated as the primary objectives were achieved following completion of Arms A to C.
Overall Study
| Stage | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg |
|---|---|---|---|
| STARTED | 8 | 6 | 6 |
| COMPLETED | 8 | 6 | 6 |
| NOT COMPLETED | 0 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: All participants who complied with the protocol sufficiently to ensure that generated data will be likely to exhibit the effects of treatment, according to the underlying scientific model, are included.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: There were no participants in Panel D.
| Characteristic | Unit | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel C: MK-8527 0.25 mg | Total |
|---|---|---|---|---|---|
| Participants analysed | 8 | 6 | 6 | 20 | |
| Age, Continuous | years | 30.0 (SD 8.6) | 23.8 (SD 3.5) | 37.8 (SD 12.6) | 30.5 (SD 10.2) |
| Sex: Female, Male: Female | Participants | 5 | 6 | 2 | 13 |
| Sex: Female, Male: Male | Participants | 3 | 0 | 4 | 7 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 8 | 6 | 6 | 20 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 8 | 6 | 2 | 16 |
| Race (NIH/OMB): White | Participants | 0 | 0 | 4 | 4 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 |
6. Primary Endpoint
The registry lists the primary outcome as Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA), measured over Baseline and 168 hours postdose on Day 1.
| Element | Registry entry |
|---|---|
| Result type | Least Squares Mean |
| Measure of spread | 95% Confidence Interval |
| Unit | HIV-1 RNA copies/mL |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is change from baseline in plasma HIV-1 RNA, measured in copies/mL, at 168 hours after a single dose on Day 1. The registry specifies a least-squares mean and a 95% confidence interval as the summary measure. It describes the analysis population as participants who complied with the protocol sufficiently for their data to be likely to exhibit treatment effects according to the underlying scientific model.
HIV-1 RNA is a continuous laboratory measure of viral genetic material in plasma. Change from baseline focuses on how the measurement differs after dosing relative to each participant’s starting value. The trial’s stated hypothesis used a reduction of ≥1.0 log10 copies/mL as the threshold for antiviral activity, at a dose considered safe and generally well tolerated. That threshold is part of the stated hypothesis, not a result.
In general, a continuous endpoint can retain information across the range of measured values instead of reducing measurements to categories. A confidence interval communicates the precision of an estimated mean change and the range of values compatible with the analysis under its assumptions. The registry record does not report the mean change, confidence interval limits, or a numerical test result. As a result, the magnitude and precision of the primary endpoint cannot be assessed from the recorded results.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record identifies the primary endpoint and its assessment time, but it does not report a numerical estimate of mean change in plasma HIV-1 RNA, a confidence interval, or a p-value. The central efficacy-related result therefore cannot be interpreted quantitatively from the record. In particular, it is not possible to determine from the recorded endpoint information whether the estimated reduction reached the stated threshold of ≥1.0 log10 copies/mL, or how uncertain any estimate was.
The study’s design also limits what comparisons can establish. Allocation is listed as nonrandomized, and the trial is described as sequential and unmasked. Dose groups in such a design are not equivalent to randomized groups. Any numerical differences between them, if reported elsewhere, could reflect differences in participants or study conduct as well as dose. The registry record does not describe a control group receiving no MK-8527 or another intervention.
The stated outcome population is restricted to participants considered sufficiently compliant with the protocol for their data to reflect treatment effects under the scientific model. The registry does not give the number included in that analysis, the criteria used to assess compliance, or how missing measurements were handled. Enrollment and analysis populations should not be assumed to be identical.
The adverse-event record lists no participants affected by a serious adverse event in the three dose groups: the group listings report 0 of 8, 0 of 6, and 0 of 6 affected, respectively. Deaths are listed as 0 for each group. These observations describe the recorded study participants; they do not establish that serious events cannot occur. The groups are small, exposure was a single dose, and the registry does not provide additional follow-up detail in the registry record recorded. Other adverse events are listed as affecting 5 of 8, 5 of 6, and 2 of 6 participants, respectively. Those counts do not identify the event types in the record’s serious-event terms.
Overall, the registry describes a completed early-phase study with virologic, pharmacokinetic, and safety objectives, but key numerical primary endpoint results are not reported in the registry record. This limits conclusions about the observed antiviral activity and its precision. The design and recorded outcomes are best understood as descriptive evidence from a small, nonrandomized, single-dose study rather than as a randomized comparison of doses.
9. Statistical Methods Explained
The primary endpoint is a continuous outcome: change in plasma HIV-1 RNA from baseline to 168 hours after dosing. The registry says that the result is summarized as a least-squares mean with a 95% confidence interval. A least-squares mean is a model-based estimate of an average. The registry record does not report the model specification, covariates, transformation of the RNA measure, or other details needed to identify precisely how that estimate was produced.
What does a confidence interval convey?
In general, a confidence interval expresses statistical uncertainty around an estimate. A narrower interval indicates greater precision under the model and assumptions used; a wider interval indicates less precision. It is not a guarantee that the true value lies within the displayed interval for an individual study. Here, the confidence interval limits are not reported in the registry record, so its precision cannot be judged.
What does the stated threshold mean?
The trial’s primary hypothesis describes antiviral activity as a reduction from baseline of ≥1.0 log10 copies/mL at a dose that is safe and generally well tolerated. This is a threshold stated in the study summary. It is distinct from the observed mean change: deciding whether the data support the threshold would require the result and its uncertainty, neither of which is reported in the registry record. A stated hypothesis should not be treated as evidence that the threshold was met.
Why does the allocation design matter?
Random allocation can help balance measured and unmeasured participant characteristics across comparison groups. This trial is listed as nonrandomized, so that protection is not described. Its sequential model also means the dose groups should not automatically be treated as concurrent, exchangeable groups. In general, comparisons across nonrandomized groups can be affected by participant differences, timing, or other features of study conduct. The registry record does not report the sequence rules or a detailed comparative analysis plan.
Masking is listed as none. In general, lack of masking can influence subjective assessments or decisions about reporting, although the primary endpoint is a laboratory measurement. The record does not describe further safeguards, laboratory masking, or endpoint adjudication; those details are not reported in the registry record.
How should pharmacokinetic outcomes be distinguished?
The secondary outcomes include area-under-the-curve measures, maximum concentration, concentration at 168 hours, time to maximum concentration, apparent terminal half-life, and plasma exposure. These characterize concentrations over time for MK-8527 or its triphosphate form in peripheral blood mononuclear cells. They answer questions about drug exposure, not the primary question about change in plasma HIV-1 RNA. The registry lists 17 outcome measures but does not report numerical outcome estimates in the registry record recorded.
What is over-dispersion, in general?
For outcomes analyzed with a count model, over-dispersion means that observed variation is greater than the model’s assumed variation. If it is ignored, uncertainty estimates may be too small and statistical evidence may appear stronger than warranted. The primary endpoint in this record is identified as a continuous measure summarized with a mean and confidence interval, not as a count outcome. The registry does not report the model details or diagnostics, so no conclusion about over-dispersion in the primary analysis is possible.
What do planning illustrations mean?
In general, sample-size planning asks how many participants would be needed to detect a specified effect under stated assumptions. The record’s planning description refers to a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and effects defined as fractions of an observed effect. Such calculations are illustrations, not observed study results or observed power. The numerical planning estimates and observed effect needed to interpret them are not reported in the registry record. They should not be confused with the trial’s enrollment of 20.
The record lists no analysis entries. It also does not report the test used for the primary endpoint, a multiplicity adjustment, interim analyses, model diagnostics, or sensitivity analyses. Those methods cannot be inferred from the endpoint label or the study objectives.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists 17 outcome measures, including the primary HIV-1 RNA endpoint and multiple pharmacokinetic outcomes. When a study evaluates several outcomes or makes multiple comparisons, the chance of at least one apparently notable result can increase. In general, multiplicity procedures may control that risk by adjusting how results are evaluated. The registry record does not report whether any multiplicity strategy was planned or used, and the record lists no analysis entries.
Missing-data handling is also not reported in the registry record. The primary endpoint description refers to a population of participants whose protocol compliance was sufficient for data to be likely to exhibit treatment effects according to the underlying scientific model. However, the record does not specify the number included in this population, the exact compliance criteria, how missing baseline or 168-hour measurements were treated, or whether any sensitivity analyses were conducted.
The listed enrollment is 20, while adverse-event groups list 8, 6, and 6 participants at risk. These safety denominators do not establish how many participants contributed to the primary endpoint analysis. Nor does the record explain whether all enrolled participants completed the endpoint assessment. The analysis population and missing-data assumptions therefore cannot be reconstructed from the registry information.
In general, missing measurements can affect an estimated mean if the participants with observed data differ systematically from those without measurements. The extent and direction of any such effect depend on why data are missing and on the analysis method. Since neither the missingness pattern nor the method is reported, the impact cannot be assessed. The record also does not report a prespecified statistical analysis plan or interim-analysis procedures.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Panel A: MK-8527 1.0 mg | 0 | 8 | 0.0% |
| Panel B: MK-8527 0.5 mg | 0 | 6 | 0.0% |
| Panel D: MK-8527 0.25 mg | 0 | 6 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Panel A: MK-8527 1.0 mg | 0 of 8 |
| Panel B: MK-8527 0.5 mg | 0 of 6 |
| Panel D: MK-8527 0.25 mg | 0 of 6 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Panel A: MK-8527 1.0 mg | 5 of 8 |
| Panel B: MK-8527 0.5 mg | 5 of 6 |
| Panel D: MK-8527 0.25 mg | 2 of 6 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Panel A: MK-8527 1.0 mg | Panel B: MK-8527 0.5 mg | Panel D: MK-8527 0.25 mg |
|---|---|---|---|---|
| Headache | Nervous system disorders | 2 of 8 | 1 of 6 | 1 of 6 |
| Impetigo | Infections and infestations | 1 of 8 | 1 of 6 | 0 of 6 |
| Tinea faciei | Infections and infestations | 1 of 8 | 1 of 6 | 0 of 6 |
| Urinary tract infection | Infections and infestations | 1 of 8 | 1 of 6 | 0 of 6 |
| Conjunctivitis allergic | Eye disorders | 1 of 8 | 0 of 6 | 0 of 6 |
| Diarrhoea | Gastrointestinal disorders | 0 of 8 | 1 of 6 | 0 of 6 |
| Dyspepsia | Gastrointestinal disorders | 0 of 8 | 0 of 6 | 1 of 6 |
| Nausea | Gastrointestinal disorders | 0 of 8 | 1 of 6 | 0 of 6 |
| Vessel puncture site bruise | General disorders | 0 of 8 | 1 of 6 | 0 of 6 |
| Carbuncle | Infections and infestations | 0 of 8 | 1 of 6 | 0 of 6 |
The serious adverse-event listing reports 0 participants affected in each of the three dose groups. The corresponding numbers at risk are 8 for the 1.0 mg group, 6 for the 0.5 mg group, and 6 for the group listed as 0.25 mg. Deaths are listed as 0 in each group. No serious-event terms are listed.
These are descriptive counts from the registry record. A count of zero observed serious events does not show that the risk is absent; it means none were recorded among the participants listed during the study’s recorded observation. The group sizes are small, and the trial evaluated a single dose. The record does not provide further detail about the duration of safety follow-up or event ascertainment, so these counts should not be extended beyond the information recorded.
The registry also lists other adverse events affecting 5 participants in the 1.0 mg group, 5 in the 0.5 mg group, and 2 in the 0.25 mg group. These are separate from the serious-event counts. The record does not identify the specific other-event terms in the registry record recorded. The adverse-event listing labels the 0.25 mg group Panel D, although its arm description calls it Panel C; the record does not explain that label difference.
12. What the Result Does, and Does Not, Mean
The study is described as a single-dose investigation of MK-8527 in ART-naïve participants with HIV-1 infection. Its aims include safety, tolerability, drug exposure, and antiviral activity. The primary virologic measure is change in plasma HIV-1 RNA from baseline to 168 hours after dosing, with a stated hypothesis involving a reduction of ≥1.0 log10 copies/mL.
The registry record does not report the numerical primary endpoint estimate or its confidence interval. Consequently, the recorded information does not show the size or precision of the mean change, nor whether it reached the stated threshold. The pharmacokinetic outcomes are listed, but their numerical results are also not reported in the registry record. The existence of an endpoint or hypothesis is not itself evidence of an observed effect.
The study’s nonrandomized, unmasked, sequential design does not support treating dose groups as randomized comparisons. Any differences between groups would need to be interpreted with caution because the record does not establish that groups were comparable in other respects. The trial also had a small enrollment and involved a single dose, so its recorded observations do not characterize longer-term exposure or outcomes.
The serious-event counts are zero in each listed group, with no deaths listed. These counts describe what was recorded in the study and do not establish that serious events cannot occur. The registry’s other adverse-event counts are not accompanied by event descriptions, and therefore cannot be characterized by type.
In short, the record describes the study question, design, and selected safety counts, but not the central numerical virologic result. Conclusions about the magnitude, precision, and statistical evidence for antiviral activity are not possible from the recorded endpoint results. The study should be interpreted as an early-phase, single-dose investigation rather than as a definitive comparison of dose groups or a source of long-term evidence.
13. Why This Trial Matters Statistically
This study illustrates a distinction that matters in clinical statistics: a well-defined endpoint and a stated hypothesis do not replace numerical results. The registry specifies change in plasma HIV-1 RNA at 168 hours and identifies a least-squares mean with a 95% confidence interval. Without the estimate and interval, readers cannot assess the magnitude or precision of the primary outcome.
It also highlights why design labels matter. Nonrandomized, sequential dose groups are not equivalent to randomized comparison groups. Statistical interpretation depends not only on the endpoint but also on how participants entered each group and what comparisons the design supports. The registry does not report enough detail to reconstruct the allocation sequence or a comparative analysis plan.
Early-phase studies can bring together different kinds of evidence. Here, the registry’s objectives include safety, tolerability, pharmacokinetics, and antiviral activity. Concentration measures address exposure, while the HIV-1 RNA endpoint addresses a virologic response. Keeping those questions distinct helps prevent pharmacokinetic descriptions or safety counts from being mistaken for the primary efficacy result.
Finally, the record illustrates limits in interpreting zero serious-event counts from small groups and a single-dose study. Such counts are useful descriptions of observed events, but they are not proof that events are impossible. Clear reporting of analysis populations, missing data, model details, and numerical outcome estimates is important for judging both uncertainty and the scope of conclusions. Several of those details are not reported in the registry record.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The main limitation for statistical interpretation is that the registry record does not report the numerical primary endpoint result, its confidence interval, or a test result. The stated antiviral-activity threshold therefore cannot be compared with an observed estimate using the information recorded. Numerical results for the listed pharmacokinetic outcomes are also not reported in the registry record.
The design is nonrandomized, unmasked, and sequential. The registry does not describe the detailed allocation sequence, whether groups were enrolled concurrently, or the rules governing progression through doses. Without those details, comparisons across dose groups cannot be treated as controlled causal contrasts. The arm-label difference for the 0.25 mg group is also unexplained: the arm description calls it Panel C, while the adverse-event listing calls it Panel D.
The record describes an analysis population based on sufficient protocol compliance but does not state its size or operational criteria. Missing measurements, exclusions, and their handling are not reported in the registry record. The statistical model, any covariates, sensitivity analyses, multiplicity procedures, and interim analyses are also not reported.
Safety observations are limited to the counts recorded for the listed groups. The registry does not provide the serious-event terms, which are empty, or descriptions of the other adverse events in the registry record recorded. Further detail about safety follow-up is not reported in the registry record. Finally, the study concerns a single dose and does not provide evidence about longer-term outcomes in the information recorded.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) — NCT05494736.
- Registry record last updated 2025-03-26; status last verified 2025-03.
- Results first posted 2025-03-26.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry describes a completed phase 1, nonrandomized, unmasked, sequential, single-dose study of MK-8527 in ART-naïve participants with HIV-1 infection. Enrollment was 20. The dose descriptions are single oral doses of 1.0 mg, 0.5 mg, and 0.25 mg. The brief summary says a fourth arm was planned but not initiated after completion of Arms A to C.
The primary endpoint is mean change from baseline in plasma HIV-1 RNA at 168 hours after dosing, reported as a least-squares mean with a 95% confidence interval. The registry record does not report the numerical primary result or its interval. Secondary outcomes cover pharmacokinetic measures of MK-8527 and its triphosphate form.
Serious adverse events and deaths are listed as 0 in each of the three dose groups. The record lists 17 outcome measures and no analysis entries. Details on the analysis model, missing-data handling, multiplicity, and the primary analysis population are not reported in the registry record.